- Medically Reviewed by: Mr Mfazo Hove, Consultant Ophthalmic Surgeon
- Author: Mr Mfazo Hove
- Published: October 2, 2025
- Last Updated: October 22, 2026
TL;DR: They look related and share the same causes, but they behave differently. A pinguecula stays on the white of the eye and does not grow across the cornea, the clear front surface of the eye. A pterygium grows onto the cornea, can change its shape, and is more likely to return after removal.
Same causes, different behaviour. The question is always whether the cornea is involved.
Infographic: 5 Differences Between Pterygium and Pinguecula
1. Where It Grows
A pinguecula stays on the conjunctiva, the thin membrane covering the white of the eye, beside the cornea. A pterygium crosses the edge of the cornea and grows onto it, usually from the side nearest the nose.
Both favour that inner corner, possibly because light entering from the side is focused there by the cornea. ¹
A pinguecula: the small yellowish patch on the white of the eye, beside the cornea on the side nearest the nose.
A pterygium growing from the white of the eye onto the cornea, on the side nearest the nose.
2. What It Looks Like
A pinguecula is yellowish, raised and rounded. A pterygium is pink or red, fleshy and wedge-shaped, with its point on the cornea.
Both are linked with sun, wind and dust, and pterygium in particular is more common in sunnier climates and in people who spend long periods outdoors. ²
3. Whether It Affects Vision
A pinguecula does not grow onto the cornea or block the line of sight. However, a raised, inflamed pinguecula can unsettle the tear film, the thin layer of tears covering the eye’s surface, and affect comfort and the quality of vision.
A pterygium can affect vision directly in two ways:
- By pulling on the cornea and inducing astigmatism, an uneven curvature that can blur or distort vision.
- By reaching the line of sight if it grows far enough.
That is why a pterygium is measured and watched, and why surgery is often advised before it reaches the centre of the cornea.
4. How Common It Is
Pinguecula is much more common. In the Blue Mountains Eye Study, it was found far more often than pterygium. ³ Many people have a pinguecula and never know.
5. How It Is Treated, and Whether It Comes Back
Pinguecula Treatment
Excision, meaning surgical removal, aims to remove the pinguecula in a single procedure. Recurrence, meaning the growth returning after treatment, is uncommon.
Laser is an option for selected small growths, but in our experience a meaningful proportion of patients needed repeat treatment. This is why Blue Fin Vision® now uses excision for most patients.
Pterygium Treatment
Recurrence is the main concern, and surgical technique is what reduces it.
Covering the area with a conjunctival autograft, a small graft of your own conjunctival tissue, lowers the risk of recurrence compared with amniotic membrane grafting. ⁴ An amniotic membrane graft uses donated tissue from the membrane surrounding a baby during pregnancy.
A report by the American Academy of Ophthalmology found that conjunctival autograft lowers recurrence compared with leaving the white of the eye bare. ⁵
Recurrence is more likely in younger patients, whose healing response is more vigorous.
What This Means for You
If you have a yellowish bump that is not bothering you, sunglasses and lubricating drops are often all you need.
If you have a fleshy growth creeping onto the cornea, or either growth is irritated, affecting contact lens wear or bothering you cosmetically, an assessment will tell you which it is and whether removal would help.
At Blue Fin Vision®, pinguecula surgery is available at Harley Street, Chelmsford and Hatfield. Pterygium surgery is available at Weymouth Street Hospital, Chelmsford and Hatfield.
For further information, read the following pages:
- Pterygium and Pinguecula Removal
- Suitability
- Risks
- Patient Information
- Pinguecula vs Pterygium: Understanding Common Eye Growths.
Book a consultation at a Blue Fin Vision® eye clinic to assess a suspected pinguecula or pterygium and discuss whether treatment is appropriate for you.
References
- Coroneo MT. Pterygium as an early indicator of ultraviolet insolation: a hypothesis. Br J Ophthalmol. 1993;77(11):734-9.
- Liu L, Wu J, Geng J, Yuan Z, Huang D. Geographical prevalence and risk factors for pterygium: a systematic review and meta-analysis. BMJ Open. 2013;3(11):e003787. doi:10.1136/bmjopen-2013-003787.
- Panchapakesan J, Hourihan F, Mitchell P. Prevalence of pterygium and pinguecula: the Blue Mountains Eye Study. Aust N Z J Ophthalmol. 1998;26 Suppl 1:S2-5.
- Clearfield E, Muthappan V, Wang X, Kuo IC. Conjunctival autograft for pterygium. Cochrane Database Syst Rev. 2016;2(2):CD011349. doi:10.1002/14651858.CD011349.pub2.
- Kaufman SC, Jacobs DS, Lee WB, Deng SX, Rosenblatt MI, Shtein RM. Options and adjuvants in surgery for pterygium: a report by the American Academy of Ophthalmology. Ophthalmology. 2013;120(1):201-8.
ABOUT THE AUTHOR
Mr Mfazo Hove
MBChB MD FRCOphth CertLRS
Consultant Ophthalmic Surgeon | Founder and Medical Director, Blue Fin Vision®
Mr Mfazo Hove is a Consultant Ophthalmic Surgeon with more than two decades of experience across NHS and private practice and more than 57,000 ophthalmic procedures performed. He trained for six and a half years at Moorfields Eye Hospital and served for five years as an NHS consultant at the Western Eye Hospital, Imperial College Healthcare NHS Trust.
He specialises in cataract surgery, refractive lens replacement, laser vision correction and implantable Collamer lenses (ICL). He is the founder and Medical Director of Blue Fin Vision®, a private ophthalmology group providing consultant-delivered care across London, Hertfordshire and Essex. His cataract surgery outcomes are publicly reported through the National Ophthalmology Database.
A ZEISS Key Opinion Leader and international speaker, Mr Hove is a contributing author to The Ophthalmologist. His writing examines how clinical governance and the organisation of ophthalmic services shape patients’ experiences and outcomes, with a focus on transparent outcome reporting, surgical training and long-term accountability for patient care.
